The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.

Division of Neuro-Oncology, Department of Neurology, Stanford Advanced Medicine Center, 875 Blake Wilbur Drive, CC2221, Stanford, CA 94305-5826, USA. snagpal@stanford.edu

Neurosurgery clinics of North America 2012 Apr

filter terms:

The 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; carmustine) polymer wafer (Gliadel) was developed for use in malignant glioma to deliver higher doses of chemotherapy directly to tumor tissue while bypassing systemic side effects. Phase III clinical trials for patients with newly diagnosed malignant gliomas demonstrated a small, but statistically significant, improvement in survival. However, the rate of complications, including an increase in cerebrospinal fluid leaks and intracranial hypertension, has limited their use. This article reviews the current data for use of BCNU wafers in malignant gliomas. Copyright Â© 2012 Elsevier Inc. All rights reserved.

Citation

Seema Nagpal. The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. Neurosurgery clinics of North America. 2012 Apr;23(2):289-95, ix